Selinexor

The FDA granted accelerated approval to selinexor for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who received at least two prior lines of systemic therapy.

Selinexor and daratumumab in combination with dexamethasone was effective in patients with relapsed/refractory multiple myeloma, according to a presentation from ASCO20 Virtual Scientific Program.

Once weekly selinexor, carfilzomib and dexamethasone showed an overall response rate of 72% in patients with relapsed/refractory multiple myeloma who have received a median of four lines of prior therapy, according to data presented at ASCO20 Virtual Scientific Program.

The addition of selinexor to bortezomib and dexamethasone significantly extended PFS among patients with multiple myeloma who received one to three prior lines of therapy, according to randomized phase 3 study results released by the agent’s manufacturer.